TREATMENT ISSUES IN TYPE 1 DIABETES - APPROACHES TO INSULIN ADMINISTRATION AND HYPOGLYCEMIA

Abstract
The topic of approaches to insulin treatment is of great importance in the management of type 1 diabetes, and has growing applicability to all forms of diabetes as we strive for optimized glycemia. Strategies for insulin use for persons with type 1 diabetes involve focus on overall glycemic management and use of the new short-acting meal-related and long-acting basal insulin analogs. This article is based on a previous review. ( )

Key words
Diabetes tipo 1, administración de insulina, bomba de insulina

Bibliografía del artículo

1. Bloomgarden ZT. Treatment Issues in Type 1 Diabetes. Diabetes Care 2002;25:230-236
2. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects Diabetes Care 1993;16: 1592-1597.
3. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 22:137-140, 1999
4. Lepore et al. 285-PP(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649)
5. Sarui et al. 105-OR(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649)
6. Solvig et al. (531-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649)
7. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta­analysis of randomised controlled trials. BMJ 2002;324:1–6
8. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin Pump Therapy: A meta-analysis. Diabetes Care, April 1, 2003; 26(4): 1079 - 1087.
9. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care, 23:1232-1235, 2000
10. Saudek CD, Selam JL, Pitt HA, Waxman K, Rubio M, Jeandidier N, Turner D, Fischell RE, Charles MA: A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med 321:574–579, 1989
11. Saudek CD, Duckworth WC, GiobbieHurder A, Henderson WG, Henry RR, Kelley DE, Edelman SV, Zieve FJ, Adler RA, Anderson JW, Anderson RJ, Hamilton BP, Donner TW, Kirkman MS, Morgan NA: Implantable insulin pump vs. multiple-dose insulin for non-insulindependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA 276:1322–1327, 1996
12. Gatcomb and Boland (551-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
13. Holl et al. (272-OR(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
14. Davis et al. (218-OR(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
15. Cersosimo et al. (219-OR(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
16. Kalergis M, Schiffrin A, Gougeon R, Jones PJH, Yale J-F.Impact of Bedtime Snack Composition on Prevention of Nocturnal Hypoglycemia in Adults With Type 1 Diabetes Undergoing Intensive Insulin Management Using Lispro Insulin Before Meals A randomized, placebo-controlled, crossover trial. Diabetes Care 26:9-15, 2003
17. .Cheyne et al. (544-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
18. Sood et al. (561-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
19. Fanelli et al. (546-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
20. Heller et al. (552-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
21. Ford-Adams et al. (548-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649))
22. Kern et al. (556-P(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1–A649)

Autoevaluación